an Asia/Pacific private equity fund in the life sciences, cleantech and information communication technologies (ICT). He was previously President & COO/CEO for EntreMed Pharmaceuticals (Nasdaq: ENMD), a clinical-stage pharmaceutical company committed to developing a selective angiogenic kinase inhibitor, for the treatment of cancer. Prior to EntreMed, Mr. Campbell served as Senior Director of Commercial Development for Celera Genomics (NASDAQ:CRA), where he built global genomic & proteomic businesses around the human genome project.
Mr. Campbell has held General & Executive Management positions at Life Technologies, Inc. (NASDAQ: LIFE), IGEN, Inc., acquired by Roche (NASDAQ:IGEN), and Abbott Laboratories (NYSE: ABT) the global diversified healthcare company. Mr. Campbell was also a member of the Adjunct Faculty for many years of the Carey Graduate School of Business at the Johns Hopkins University and lectured in the JHU Medical Institutes as part of a joint business/medicine program. Mr. Campbell is now a visiting professor/research fellow at universities in the USA, Europe and Asia.
Full biographies, unique experience, expertise & accomplishments of each advisory board member:
- Neil J. Campbell,
M.A., M.B.A. – Chairman - Kevin Carroll
- Edward L. Erickson
- Daniel D'Agostino
- Nigel Gaymond, M.A.
- David M. Koeninger
- Udo Klein, Ph.D.
- Stefan Loren, Ph.D.
- Kevin Nickels
- Rick Pierce
- Robin Pratt, Ph.D.
- Linda M. Pullan, Ph.D.
- Dane Saglio, C.P.A.
- Peter G. Savas
- Chris Ward
- Ruth Williams, Esq.
Neil J. Campbell is President and CEO of SuperNova Diagnostics®, Inc, a privately held global diagnostics company with a proprietary platform for conducting diagnostics at the site of interest with point-of-care in human health and point-of-use for non-human health applications. SuperNova Diagnostics has offices in Washington, D.C., London and Hong Kong. AmpCrystal®, SuperNova Diagnostics' lead technology and its multiple product formats, allows for minimally trained individuals (advanced CLIA-waived) to test for a wide range of protein analytes and can detect directly un-amplified DNA in humans, animals or environmental samples. Time-to-result has been shown in prototypes to be reduced to minutes on the spot versus the hours or days required when sending samples to a central laboratory or processing in regional satellite laboratories. The technology is simpler, more robust, faster and significantly less expensive than existing POC systems. Additionally, Mr. Campbell also serves as Executive Chairman for Mosaigen® Corporation, a global technology development corporation with offices in America, Europe and Asia, and Chairman for Child Health Research Institute, a global children's charity.
Having held several key positions at a number of multinational pharmaceutical, healthcare, investment and life science companies, Mr. Campbell has more than 20 years of industry experience. Formerly, Mr. Campbell was a General Partner for Endeavour Capital,
 |
|||||||||
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
|||||||||